Evidence map›Paper›PMID 42210236›Full record

ArticleMolecular cancer2026

Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer.

Fang-Lin Zhang, Shao-Ying Yang, Yin-Ling Zhang, Qian Zhao, Wen-Xiao Yang, Lisa Andriani, Jia-Yang Cai, Min-Ying Huang, Xin Hu, Zhi-Min Shao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fang-Lin Zhang *Department of Oncology, Cancer Institute, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. zhangfanglin555@sina.com.
Shao-Ying Yang *Department of Oncology, Cancer Institute, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Yin-Ling Zhang *Department of Oncology, Cancer Institute, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Qian Zhao *Department of Oncology, Cancer Institute, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Wen-Xiao YangPrecision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lisa AndrianiDepartment of Breast Surgery, Shanghai Key Laboratory of Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Jia-Yang CaiDepartment of Breast Surgery, Shanghai Key Laboratory of Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Min-Ying HuangInstitutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Xin HuDepartment of Oncology, Cancer Institute, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Zhi-Min ShaoDepartment of Oncology, Cancer Institute, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
A-Yong CaoDepartment of Breast Surgery, Shanghai Key Laboratory of Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. caoayong@fudan.edu.cn.
Da-Qiang LiDepartment of Oncology, Cancer Institute, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. daqiangli1974@fudan.edu.cn.

Funding

National Natural Science Foundation of China 82372633National Natural Science Foundation of China 82573892
6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) has shown limited efficacy in triple-negative breast cancer (TNBC), highlighting the need to elucidate mechanisms of immune evasion and identify novel therapeutic targets. Here, we identify MORC family CW-type zinc finger 2 (MORC2), an ATP-dependent chromatin remodeler, as a key epigenetic suppressor of antitumor immunity in TNBC. MORC2 is significantly upregulated in TNBC and correlates with an immunosuppressive tumor microenvironment and poor response to ICB. Genetic ablation of MORC2 inhibited tumor growth in immunocompetent but not immunodeficient mice, accompanied by enhanced CD8

Indexed as

Immune Checkpoint InhibitorsMolecular MimicryTranscription FactorsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHistone-Lysine N-MethyltransferaseHumansMiceTumor MicroenvironmentHistone-Lysine N-MethyltransferaseImmune Checkpoint InhibitorsSETDB1 protein, humanTranscription FactorsChromatin remodelingImmunotherapyTranscriptional repressionTriple-negative breast cancerTumor immune microenvironment

Identifiers

PMID42210236
PMCPMC13420440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.